Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic FunctionSuleiman Massarweh, Rachel Schiff, C. Kent Osborne et al.|Cancer Research|2008Cited by 494
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancerNoor Mazin Abdulkareem, Meghana V. Trivedi, Raksha R. Bhat et al.|The FASEB Journal|2021Cited by 25
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancerRaksha R. Bhat, Meghana V. Trivedi, Ahmed Al-Rawi et al.|Breast Cancer Research and Treatment|2018Cited by 25
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancerXiaoyong Fu, Rachel Schiff, Resel Pereira et al.|Cell Reports|2023Cited by 20
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft modelsJamunarani Veeraraghavan, Rachel Schiff, Carolina Gutiérrez et al.|npj Breast Cancer|2021Cited by 11